肛门癌,2023年第2版,NCCN肿瘤临床实践指南
本指南总结了NCCN关于肛管鳞状细胞癌(最常见的组织学类型)的诊疗推荐,强调包括消化内科、肿瘤内科、肿瘤外科、放疗科和放射科的多学科协作;肛周癌与肛管癌以放化疗为主要治疗,所有患者均应随访临床评估,局部复发或持续病灶可手术,盆腔外转移一般推荐全身治疗;近期更新包括基于AJCC第9版分期的分期分类及转移性肛门癌全身治疗推荐。
要点
- 肛周癌与肛管癌的主要治疗相似,多数病例采用放化疗。
- 所有肛门癌患者均应进行随访临床评估,因仍可能行根治性治疗。
- 原发治疗后活检证实局部复发或持续病灶,可能需要手术治疗。
核心结论
- NCCN指南推荐对肛管鳞状细胞癌采用多学科协作,以放化疗为主要治疗,所有患者应随访临床评估,活检证实的局部复发或持续病灶可手术,盆腔外转移一般推荐全身治疗。
研究设计与样本
- NCCN肿瘤临床实践指南,由多学科团队制定,涵盖消化内科、肿瘤内科、肿瘤外科、放疗科和放射科医师;近期更新包括基于AJCC第9版分期的分期分类和转移性肛门癌全身治疗推荐。
临床应用与阅片要点
- 肛周癌和肛管癌的主要治疗相似,多数病例包括放化疗。
- 所有肛门癌患者推荐随访临床评估,因为仍可能进行根治性治疗。
- 原发治疗后活检证实局部复发或持续病灶可能需要手术治疗。
- 盆腔外转移性病变一般推荐全身治疗。
- 近期更新包括基于AJCC第9版分期的分期分类和转移性肛门癌的全身治疗推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
This discussion summarizes the NCCN Clinical Practice Guidelines for managing squamous cell anal carcinoma, which represents the most common histologic form of the disease. A multidisciplinary approach including physicians from gastroenterology, medical oncology, surgical oncology, radiation oncology, and radiology is necessary. Primary treatment of perianal cancer and anal canal cancer are similar and include chemoradiation in most cases. Follow-up clinical evaluations are recommended for all patients with anal carcinoma because additional curative-intent treatment is possible. Biopsy-proven evidence of locally recurrent or persistent disease after primary treatment may require surgical treatment. Systemic therapy is generally recommended for extrapelvic metastatic disease. Recent updates to the NCCN Guidelines for Anal Carcinoma include staging classification updates based on the 9th edition of the AJCC Staging System and updates to the systemic therapy recommendations based on new data that better define optimal treatment of patients with metastatic anal carcinoma.
引用
- Benson AB, Venook AP, Al-Hawary MM, et al. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023. PMID: 37308125. doi:10.6004/jnccn.2023.0030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。